{"organizations": [], "uuid": "c35f467e9c4aa76a769b6c4abdc6d5addab03e4e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180523.html", "section_title": "Archive News &amp; Video for Wednesday, 23 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-cara-therapeutics-and-vifor-fresen/brief-cara-therapeutics-and-vifor-fresenius-medical-care-renal-pharma-enter-into-ex-u-s-licensing-agreement-idUSFWN1SU0D2", "country": "US", "domain_rank": 408, "title": "BRIEF-Cara Therapeutics And Vifor Fresenius Medical Care Renal Pharma Enter Into Ex-U.S. Licensing Agreement", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.519, "site_type": "news", "published": "2018-05-23T18:11:00.000+03:00", "replies_count": 0, "uuid": "c35f467e9c4aa76a769b6c4abdc6d5addab03e4e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-cara-therapeutics-and-vifor-fresen/brief-cara-therapeutics-and-vifor-fresenius-medical-care-renal-pharma-enter-into-ex-u-s-licensing-agreement-idUSFWN1SU0D2", "ord_in_thread": 0, "title": "BRIEF-Cara Therapeutics And Vifor Fresenius Medical Care Renal Pharma Enter Into Ex-U.S. Licensing Agreement", "locations": [], "entities": {"persons": [{"name": "vifor", "sentiment": "negative"}, {"name": "cara", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "south korea", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "cara therapeutics inc", "sentiment": "negative"}, {"name": "cara", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 23 (Reuters) - Cara Therapeutics Inc:\n* CARA THERAPEUTICS AND VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA (VFMCRP) ENTER INTO EX-U.S. LICENSING AGREEMENT TO COMMERCIALIZE KORSUVAâ„¢ INJECTION IN DIALYSIS PATIENTS WITH PRURITUS\n* CARA THERAPEUTICS INC - CARA ELIGIBLE FOR UP TO $470 MILLION IN REGULATORY AND COMMERCIAL MILESTONES\n* CARA THERAPEUTICS INC - VFMCRP TO COMMERCIALIZE KORSUVA INJECTION WORLDWIDE EXCEPT IN U.S., JAPAN AND SOUTH KOREA\n* CARA THERAPEUTICS INC - CARA RECEIVES UPFRONT PAYMENT OF $50 MILLION IN CASH AND AN EQUITY INVESTMENT OF $20 MILLION\n* CARA THERAPEUTICS INC - CARA IS ELIGIBLE TO RECEIVE TIERED ROYALTIES BASED ON NET SALES OF KORSUVA INJECTION IN LICENSED TERRITORIES\n* CARA THERAPEUTICS INC - CARA WILL SOLELY PROMOTE KORSUVA INJECTION IN ALL NON-FMC CLINICS IN U.S. AND RETAIN ALL PROFITS FROM THOSE SALES Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-23T18:11:00.000+03:00", "crawled": "2018-05-24T20:49:09.000+03:00", "highlightTitle": ""}